P-610 Growth inhibition of NSCLC xenografts by erlotinib is independent of HER1/2 overexpression and can reliably be monitored by serum tumor markers

Authors:
  • TFThomas Friess
    Thomas Friess
  • RJRolf Juchem
    Rolf Juchem
  • WSWerner Scheuer
    Werner Scheuer
  • MHMax Hasmann
    Max Hasmann

Abstract
No abstract available